Drug-maker Ranbaxy Laboratories has been asked to furnish details on its products eligible for reimbursements from the US Government, the company informed the Bombay Stock Exchange on Wednesday.
The company appears to have fallen foul of the US Department of Justice once again as it was sent a Civil Investigative Demand “relating to the manner in which it reports pricing data for certain products eligible for reimbursement under the Medicaid program,” Ranbaxy said in a filing to BSE.
No compensation demand The company added that this is a request for documents and information and “is not an allegation of wrongdoing or demand for compensation.”
While the company refused to divulge information on the drugs which have been called into question, a senior official from the company said it is related to the alleged over-pricing of some medicines being provided by Ranbaxy to the publicly-funded Medicaid program.
According to foreign media reports, the US is looking into the issue of drug-makers stating inflated figures for medicines to the Government for the Medicaid program leading to losses to the exchequer.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.